JBIO
NASDAQJade Biosciences Inc.
$25.04-0.20 (-0.79%)
News25/Ratings7
Price$25.04-0.70 (-2.70%)
01:30 PM07:45 PM
News · 26 weeks39+300%
2025-11-022026-04-26
Mix2390d
- SEC Filings10(43%)
- Other8(35%)
- Insider4(17%)
- Leadership1(4%)
Latest news
25 items- PRJade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO and VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that Jade's Board of Directors granted an equity award to Edward R. Conner, M.D., effective as of April 22, 2026, in connection with his appointment as Chief Medical Officer. The Board of Directors granted Dr. Conner non-qualified stock options to purchase an aggregate of 500,000 shares of the Company's common stock under the Jade Biosciences, Inc. Employment Inducement Stock Incentive Plan (the "Inducement Plan"). The op
- SECSEC Form 8-K filed by Jade Biosciences Inc.8-K - Jade Biosciences, Inc. (0001798749) (Filer)
- PRJade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical OfficerSAN FRANCISCO and VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade" or the "Company") (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the appointment of Edward R. Conner, M.D., as Chief Medical Officer (CMO), effective today. Dr. Conner is an accomplished biopharmaceutical executive with extensive experience spanning clinical development, translational medicine, regulatory strategy and mechanism-based drug development, across early- to late-stage programs. As Chief Medical Officer, he will lead Jade's clinical and medical organization, overseeing develo
- SECSEC Form PRE 14A filed by Jade Biosciences Inc.PRE 14A - Jade Biosciences, Inc. (0001798749) (Filer)
- SECSEC Form 8-K filed by Jade Biosciences Inc.8-K - Jade Biosciences, Inc. (0001798749) (Filer)
- SECSEC Form S-8 filed by Jade Biosciences Inc.S-8 - Jade Biosciences, Inc. (0001798749) (Filer)
- SECSEC Form POS EX filed by Jade Biosciences Inc.POS EX - Jade Biosciences, Inc. (0001798749) (Filer)
- SECSEC Form POS EX filed by Jade Biosciences Inc.POS EX - Jade Biosciences, Inc. (0001798749) (Filer)
- SECSEC Form 424B3 filed by Jade Biosciences Inc.424B3 - Jade Biosciences, Inc. (0001798749) (Filer)
- SECSEC Form 424B3 filed by Jade Biosciences Inc.424B3 - Jade Biosciences, Inc. (0001798749) (Filer)
- SECSEC Form 10-K filed by Jade Biosciences Inc.10-K - Jade Biosciences, Inc. (0001798749) (Filer)
- SECJade Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Jade Biosciences, Inc. (0001798749) (Filer)
- PRJade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateJADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipated in 2027JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, expected to advance into first-in-human clinical trial in rheumatoid arthritis patients in the second quarter of 2026; interim data anticipated in 2027Third development candidate, JADE301, nominated; Phase 1 clinical trial expected to commence in the first half of 2027$336 million of cash, cash equivalents, and investments as of December 31st, 2025 expected to provide runway into the first half of 2028 SAN FRANCI
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Jade Biosciences Inc.SCHEDULE 13D/A - Jade Biosciences, Inc. (0001798749) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Jade Biosciences Inc.SCHEDULE 13G/A - Jade Biosciences, Inc. (0001798749) (Subject)
- SECSEC Form SCHEDULE 13G filed by Jade Biosciences Inc.SCHEDULE 13G - Jade Biosciences, Inc. (0001798749) (Subject)
- SECSEC Form SCHEDULE 13G filed by Jade Biosciences Inc.SCHEDULE 13G - Jade Biosciences, Inc. (0001798749) (Subject)
- INSIDERChief Financial Officer Dahms Bradford D. was granted 37,813 shares (SEC Form 4)4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDEROfficer Balta Elizabeth was granted 28,125 shares (SEC Form 4)4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERChief Executive Officer Frohlich Tom was granted 78,750 shares, increasing direct ownership by 1,039% to 86,331 units (SEC Form 4)4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDEROfficer King Andrew James was granted 41,250 shares, increasing direct ownership by 12% to 386,113 units (SEC Form 4)4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- PRJade Biosciences to Participate in Upcoming ConferencesSAN FRANCISCO and VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade"), (NASDAQ:JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference | February 25-26, 2026Presentation: Thursday, February 26 at 1:20 p.m. ET |Track 3TD Cowen 46th Annual Health Care Conference | March 2-4, 2026Presentation & Fireside Chat: Monday, March 2 at 10:30 a.m. ETLeerink Global Healthcare Conference | March 8-11, 2026Fireside Chat: Wednesday, March 11 at 8:40 a.m. ETJefferies Biotech on the Beach
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Jade Biosciences Inc.SCHEDULE 13G/A - Jade Biosciences, Inc. (0001798749) (Subject)
- ANALYSTH.C. Wainwright initiated coverage on Jade Biosciences with a new price targetH.C. Wainwright initiated coverage of Jade Biosciences with a rating of Buy and set a new price target of $25.00
- SECJade Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure8-K - Jade Biosciences, Inc. (0001798749) (Filer)